US › Healthcare

Moleculin Biotech Inc (MBRX)

US · Healthcare · Biotechnology

$8.70-0.34%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.6M

EPS

$-1.40

EPS estimate

$-1.55

EPS came in at -1.40 against a street estimate of -1.55 — a beat of 9.7%.

Key statistics

Market cap

$8.9M

P/E

0.0

Forward P/E

0.0

P/B

0.75

Book value

$32.64

EPS (TTM)

$179.60

52-week high

$253.05

52-week low

$3.23

50-day MA

$10.55

200-day MA

$38.81

Beta

2.09

Analyst view

Analysts rate Moleculin Biotech Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $240.00.

Shareholding

Insiders

7.18%

Institutions

7.93%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.23%
Vanguard Capital Management, LLC	0.21%
Vanguard Fiduciary Trust Co	0.15%
XTX Topco Ltd	0.11%
Morgan Stanley - Brokerage Accounts	0.10%
Rockefeller Capital Management L.P.	0.07%
Tower Research Capital LLC	0.02%
Citigroup Inc	0.01%

Corporate actions

Action	Detail	Date
Split	1 : 20 effective Oct 20, 2026	2026-10-20

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Moleculin Biotech Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.